IPCA Laboratories Limited — Investor Meet, 14-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Ipca Labs' Q1 FY26 saw standalone net profit jump 26% with improved EBITDA margins. Consolidated net profit rose 18%, but margins saw a slight dip primarily due to Unichem. Unichem's profitability was impacted by lost market share in key US products and one-time provisions, including a Rs. 12 Cr currency impact and Rs. 10 Cr for an Ireland facility closure. Domestic business grew 10%, with strong chronic segment performance and strategic sales force expansion. Management maintained its full-year topline growth outlook but adjusted consolidated EBITDA margin improvement slightly downwards. The company remains confident in long-term growth and Unichem's recovery despite initial challenges in some subsidiaries. #IpcaLabs #Q1FY26